Schedule an appointment today
Call to Schedule: 1-866-UH4-CARE
Find Clinical Trials & Studies
Visit the Research & Education Institute

A Phase 1/2 Study of BMS-986525 with and without Nivolumab in Relapsed/Refractory SCLC

Back to Search Results
Share
Facebook
X
Pinterest
LinkedIn
Email
Print
I'm Interested!
Please call
1-866-373-1464

A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

  • Sex: Any
  • Age: Adult (18 - 64), Older Adult (65+)
  • Accepting Healthy People: No
  • Type: Interventional / Therapeutic
  • Trial Phase: Phase I
  • Conditions Being Studied: Cancer - Lung

Study Purpose

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer

Principal Investigator
Afshin Dowlati MD
Department/Division
Cancer (Thoracic)
  • UH IRB: STUDY20251640
  • StudyID: BRMY3525
  • ClinicalTrials.gov: NCT07325136
I'm Interested!
Please call
1-866-373-1464

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-866-373-1464